Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Overview: Gilead is a biopharmaceutical company focused on anti-infectives, specifically HIV, Hepatitis B, and fungal infections. The company operates in one business segment and markets eight approved products globally. Key products include Viread, Emtriva, and Truvada (HIV); Hepsera (Hepatitis B); and AmBisome (fungal infections). The company also earns royalties from Tamiflu (Roche) and Macugen (Eyetech).
Key Financial Metrics
| Metric | 2004 | 2003 | Change |
|---|---|---|---|
| Total Revenues | $1,324.6 million | $867.9 million | +53% |
| Product Sales | $1,242.2 million | $836.3 million | +49% |
| Royalty Revenue | $63.4 million | $25.2 million | +152% |
| Net Income | $449.4 million | ($72.0 million) | Turnaround to Profit |
| Diluted EPS | $0.99 | ($0.18) | N/A |
| Operating Cash Flow | $511.4 million | $234.6 million | +118% |
| Cash & Equivalents | $1,254.0 million | $707.0 million | +77% |
| Long-Term Debt | $0.2 million | $345.2 million | Eliminated |
| Gross Margin | 86.6% | 86.5% | Flat |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 53% year-over-year, driven primarily by a 58% increase in HIV product sales (Viread, Emtriva, Truvada) and a 152% surge in royalty revenue, largely due to Tamiflu sales during a severe flu season.
- Profitability Turnaround: The company moved from a net loss of $72.0 million in 2003 to a net income of $449.4 million in 2004. The 2003 loss was significantly impacted by a $488.6 million charge for purchased in-process research and development (IPR&D) related to the Triangle Pharmaceuticals acquisition.
- Debt Elimination: In November 2004, Gilead redeemed and converted its $345.0 million 2% convertible senior notes into common stock, effectively eliminating its long-term debt obligations.
- Product Launches: Truvada (a fixed-dose combination of Viread and Emtriva) was launched in the U.S. in August 2004, generating $67.9 million in sales by year-end.
- One-Time Items: 2004 included a $20.6 million gain on Eyetech warrants and a $7.4 million make-whole payment on debt redemption. 2003 included a $111.6 million tax benefit from the reversal of a valuation allowance on deferred tax assets.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- 2005 Revenue Guidance: HIV product sales are expected to range between $1.2 billion and $1.25 billion. AmBisome sales are projected between $195 million and $205 million.
- Expense Guidance: R&D expenses are expected to be $240–$260 million; SG&A expenses are expected to be $350–$370 million. Capital expenditures are projected at $55–$65 million.
- Strategic Initiatives: A joint venture with Bristol-Myers Squibb (BMS) was formed in December 2004 to develop a fixed-dose combination of Truvada and Sustiva. New collaborations in Hepatitis C (HCV) were signed with Achillion and Genelabs.
Risks and Contingencies:
- Product Concentration: HIV products and AmBisome accounted for approximately 90% of total product revenues in 2004. Future performance is heavily dependent on these products.
- Competition: Significant competition exists in HIV (e.g., GSK, BMS) and antifungal (e.g., Merck, Pfizer) markets. Generic competition for HIV drugs is emerging.
- Manufacturing Dependencies: Gilead relies on third-party contract manufacturers for its antiviral products and single suppliers for key raw materials (e.g., amphotericin B for AmBisome).
- Legal Proceedings: The company is a defendant in multiple lawsuits alleging overcharging of Medicaid programs and securities class actions regarding alleged false statements. No amounts have been accrued as outcomes are unpredictable.
- Accounting Changes: Adoption of SFAS 123(R) regarding stock-based compensation is expected in Q3 2005, which will materially impact reported earnings.
Key Facts for Investor Verification
- Revenue Mix: Verify the sustainability of HIV product growth (Viread, Emtriva, Truvada) which drove 73% of product sales, versus the flat volume growth of AmBisome.
- Debt Status: Confirm the complete elimination of the $345 million convertible debt and the associated dilution from the issuance of ~14.7 million shares.
- One-Time Gains/Losses: Assess the impact of the $20.6 million Eyetech warrant gain and the $7.4 million debt redemption cost on normalized earnings.
- European Receivables: Monitor the $231.9 million in accounts receivable from government-owned customers in Greece, Italy, Portugal, and Spain, which are subject to significant payment delays.
- Future Expenses: Track the impact of the new SFAS 123(R) standard on stock-based compensation expenses starting in the second half of 2005.